The federal government’s 2026 Unified Agenda, published July 3, puts four regulatory actions in front of HRPP and IRB leaders that could collectively reshape how institutions staff oversight committees, structure multisite study agreements, and write Phase 1 protocols. None of these are final requirements yet, but two of them carry NPRM target dates of July 2026, meaning comment windows could open before many institutions have updated their policies.
The most operationally immediate item is FDA’s planned final rule on single IRB review for multisite cooperative research, currently listed with a December 2026 effective date. The agency’s September 2022 proposed rule would convert sIRB use from a documented option to a mandate for U.S. institutions enrolled in FDA-regulated cooperative studies, with recordkeeping added whenever a site relies on an IRB it does not operate. The shift matters structurally: institutions that have treated reliance agreements as flexible arrangements will need to treat them as the default baseline. FDA’s own regulatory impact analysis cites reduced duplicative review and earlier study initiation as anticipated gains, though the final exceptions and transition provisions are still unknown.
Parallel to that, roughly 2,300 IRBs operating under FDA and OHRP oversight face a second pressure point: OHRP’s planned revision to 45 CFR 46, which would expand exemptions for low-risk research and introduce flexibility for what OHRP calls “de minimis” protocol changes. The agency frames this as a reallocation of reviewer attention toward higher-risk work, but the NPRM text is not yet public, so which research categories qualify for new exemptions remains open. OHRP itself flags the risk of inconsistent implementation across institutions, and IRB leaders running FDA-regulated portfolios will need to watch whether any expanded exemptions interact with FDA regulations or create gaps in documentation coverage.
Two additional items deserve monitoring with lower immediate urgency. FDA’s proposed Phase 1 IND reform (0910-AJ30) would introduce risk-based flexibility into application content and sponsor responsibilities, which sounds straightforward but could require institutions to revise internal policies if sponsor responsibilities shift in ways that touch IRB review criteria. The FDA-Common Rule harmonization rule (0910-AI07) carries a July 2027 target date, placing it further out, but its September 2022 NPRM was published alongside the sIRB proposed rule, and the two are easy to conflate. The practical item to track between now and year-end: whether the sIRB final rule publishes in December as listed, and what exceptions it carves out.
Source link: https://www.advarra.com/blog/2026-dhhs-unified-agenda-four-areas-hrpp-and-irb-leaders-should-watch/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
